Cel-Sci Corporation (CVM) - NYSEMKT
  • Tue, May 10, 5:11 PM
    | Tue, May 10, 5:11 PM
  • Tue, Feb. 9, 5:08 PM
    | Tue, Feb. 9, 5:08 PM | 6 Comments
  • Dec. 11, 2015, 4:48 PM
    • Cel-Sci (NYSEMKT:CVM): FY15 EPS of -$0.42 vs. -$0.49 in FY14
    | Dec. 11, 2015, 4:48 PM | 2 Comments
  • Aug. 7, 2015, 4:35 PM
    • Cel-Sci (NYSEMKT:CVM): FQ3 EPS of -$0.06 beats by $0.05.
    • Revenue of $0.39M (+3800.0% Y/Y) beats by $0.29M.
    | Aug. 7, 2015, 4:35 PM
  • May 8, 2015, 5:03 PM
    • Cel-Sci (NYSEMKT:CVM): FQ2 EPS of -$0.17 misses by $0.06.
    | May 8, 2015, 5:03 PM
  • Feb. 6, 2015, 4:52 PM
    • Cel-Sci (NYSEMKT:CVM): FQ1 EPS of -$0.11 vs. -$0.15 in Q113
    | Feb. 6, 2015, 4:52 PM | 1 Comment
  • Aug. 8, 2014, 4:30 PM
    • Cel-Sci (NYSEMKT:CVM): FQ3 EPS of -$0.11
    | Aug. 8, 2014, 4:30 PM
  • Aug. 8, 2014, 4:30 PM
    • Cel-Sci Corp. (CVM) fiscal Q3 results: Revenues: $15.9K (-86.0%); Net Loss: ($2.4M) (-45.0%); Loss Per Share: ($0.11) (-38.9%).
    • No financial guidance given.
    | Aug. 8, 2014, 4:30 PM
  • May 13, 2014, 8:35 AM
    • CEL-SCI (CVM): FQ2 EPS of -$0.24 misses by $0.13.
    | May 13, 2014, 8:35 AM
  • Feb. 11, 2014, 8:07 AM
    • CEL-SCI Corporation (CVM): FQ1 EPS of -$0.11 in-line. (PR)
    | Feb. 11, 2014, 8:07 AM
  • Aug. 9, 2013, 4:41 PM
    • CEL-SCI Corp. (CVM): FQ3 EPS of -$0.02 in-line. (PR)
    | Aug. 9, 2013, 4:41 PM
  • Feb. 8, 2013, 4:39 PM

    CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02 reported for Q1 2012. Net losses were $2.3M versus losses of $4.2M during the prior year period. R&D expenses increased by 25% Y/Y, largely due to the increased level of activity associated with conducting Phase III clinical studies. Shares -0.5% AH.

    | Feb. 8, 2013, 4:39 PM | 1 Comment
Company Description
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... More
Sector: Healthcare
Industry: Biotechnology
Country: United States